Last reviewed · How we verify

NCT05279209

Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

Status unknown NA Last updated 15 March 2022
What this trial tests

NA trial testing catheter-directed sclerotherapy in Ovarian Endometrioma in 98 participants. Status unknown.

Timeline
18 December 2021
Primary endpoint
17 December 2022
17 December 2023

Quick facts

Lead sponsorYonsei University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment98
Start date18 December 2021
Primary completion17 December 2022
Estimated completion17 December 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Yonsei University

Who can join

Adults 19 to 60, female only, with Ovarian Endometrioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to compare residual ovarian function and therapeutic efficacy of surgical resection and catheter-directed sclerotherapy for ovarian endometrioma

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ovarian Endometrioma

Currently open trials in the same condition.

Other Yonsei University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing